Conditions: Nasopharyngeal Carcinoma
Keywords: Radiotherapy chemotherapy Drug Targeting loco-regionally advanced nasopharyngeal carcinoma Safety. efficacy
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 100
Healthy volunteers: no

Brief summary:
This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Detailed description:

Arms:
arm 1: 400mg/m\^2 intravenous infusion one week before radiotherapy, then 250mg/m\^2 intravenous infusion weekly during radiotherapy

Interventions: intervention 1: C225 (cetuximab)
Intervention descriptions: intervention 1: one week before and then weekly during radiotherapy

Protocol document: